Almost a year after a licensing dispute between antibody manufacturers Biosite and Xoma turned litigious, the two parties last week announced that they had agreed to resolve their differences out of court. The happy ending to the dispute comes a bit late, however, for Large Scale Biology, which was forced to terminate its business relationship with Biosite for fear of getting caught up in litigation. For now, LSBC officials say it’s too early to comment on whether they’ll consider buying antibodies again from Biosite.